Cas no 873857-62-6 (Fidaxomicin)

Fidaxomicin is a macrocyclic antibiotic specifically designed for the treatment of Clostridioides difficile infections (CDI). Its narrow-spectrum activity selectively targets C. difficile while minimizing disruption to the gut microbiota, reducing the risk of dysbiosis and secondary infections. Fidaxomicin inhibits bacterial RNA polymerase with high specificity, exhibiting potent bactericidal effects against C. difficile strains, including some resistant to metronidazole or vancomycin. Clinical studies demonstrate its efficacy in achieving sustained clinical cure rates with lower recurrence compared to standard therapies. Its limited systemic absorption enhances localized action in the gastrointestinal tract, improving safety profiles. Fidaxomicin is particularly advantageous for recurrent CDI cases and patients requiring microbiota preservation.
Fidaxomicin structure
Fidaxomicin structure
Product Name:Fidaxomicin
CAS No:873857-62-6
MF:C52H74Cl2O18
MW:1058.03917646408
MDL:MFCD27976367
CID:836674
PubChem ID:10034073
Update Time:2025-10-28

Fidaxomicin Chemical and Physical Properties

Names and Identifiers

    • Fidaxomicin
    • R-Tiacumicin B
    • Tiacumicin B
    • OPT-80
    • PAR-101
    • 3-(((6-Deoxy-4-O-(3,5-dichloro-2-ethyl-4,6-dihydroxybenzoyl)-2-O-methyl-b-D-mannopyranosyl)oxy)-methyl)-12(R)-[(6-deoxy-5-C-methyl-4-O-(2-methyl-1-oxopropyl)-b-D-lyxo-hexopyranosyl)oxy]-11(S)-ethyl-8(S)-hydroxy-18(S)-(1(R)-hydroxyethyl)-9,13,15-trimethyloxacyclooctadeca-3,5,9,13,15-pentaene-2-one
    • Lipiarmycin
    • Clostomicin B1
    • Fidaxomycin
    • Lipiarmycin A3
    • [(2R,3S,4S,5S,6R)-6-[[(3E,5Z,8S,9E,11S,12R,13E,15E,18S)-12-[(2R,3S,4R,5S)-3,4-Dihydroxy-6,6-dimethyl
    • Dificid
    • Dificlir
    • Lipiarmicin
    • Difimicin
    • Z5N076G8YQ
    • Lipiarmycin A 3
    • Fidaxomicin [USAN:INN]
    • Lipiarrmycin
    • PAR 01
    • Clostomycin B1
    • Fidaxomicin (Dificid)
    • Fidaxomicin, >=98% (HPLC)
    • GTPL10909
    • FI8
    • DB08874
    • Q5446672
    • MDL： MFCD27976367
    • Inchi： 1S/C52H74Cl2O18/c1-13-30-22-26(6)33(56)18-16-15-17-31(23-66-51-45(65-12)42(61)44(29(9)67-51)69-49(64)35-32(14-2)36(53)39(58)37(54)38(35)57)48(63)68-34(28(8)55)20-19-25(5)21-27(7)43(30)70-50-41(60)40(59)46(52(10,11)72-50)71-47(62)24(3)4/h15-17,19,21-22,24,28-30,33-34,40-46,50-51,55-61H,13-14,18,20,23H2,1-12H3/b16-15+,25-19+,26-22+,27-21+,31-17+/t28-,29-,30+,33+,34+,40-,41+,42+,43+,44-,45+,46+,50-,51-/m1/s1
    • InChI Key： ZVGNESXIJDCBKN-UUEYKCAUSA-N
    • SMILES： ClC1=C(C(=C(C(=C1CC)C(=O)O[C@@H]1[C@@H](C)O[C@H]([C@H]([C@H]1O)OC)OCC1C(=O)O[C@H]([C@@H](C)O)CC=C(C)C=C(C)[C@@H]([C@H](C=C(C)[C@H](CC=CC=1)O)CC)O[C@H]1[C@H]([C@H]([C@@H](C(C)(C)O1)OC(C(C)C)=O)O)O)O)Cl)O |c:35,38,43,50,t:48|
    • BRN： 5228707

Computed Properties

  • Hydrogen Bond Donor Count: 7
  • Hydrogen Bond Acceptor Count: 18
  • Heavy Atom Count: 72
  • Rotatable Bond Count: 15
  • Complexity: 1970
  • XLogP3: 6.4
  • Topological Polar Surface Area: 267

Experimental Properties

  • Density: 1.33
  • Melting Point: 159.0 to 163.0 deg-C

Fidaxomicin Security Information

  • Signal Word：Warning
  • Hazard Statement： H302-H315-H319-H335
  • Warning Statement： P261-P305+P351+P338
  • Regulatory Condition Code：Class Q (sugars, alkaloids, antibiotics, hormones)
  • Storage Condition：Powder -20°C 3 years ? 4°C 2 years In solvent -80°C 6 months ? -20°C 1 month

Fidaxomicin Pricemore >>

Related Categories No. Product Name Cas No. Purity Specification Price update time Inquiry
SHANG HAI A LA DING SHENG HUA KE JI GU FEN Co., Ltd.
F129607-50mg
Fidaxomicin
 873857-62-6 ≥99%
50mg
 ￥360.90 2023-09-02
SHANG HAI A LA DING SHENG HUA KE JI GU FEN Co., Ltd.
F129607-100mg
Fidaxomicin
 873857-62-6 ≥99%
100mg
 ￥642.90 2023-09-02
SHANG HAI A LA DING SHENG HUA KE JI GU FEN Co., Ltd.
F129607-250mg
Fidaxomicin
 873857-62-6 ≥99%
250mg
 ￥1311.90 2023-09-02
SHANG HAI A LA DING SHENG HUA KE JI GU FEN Co., Ltd.
F129607-5mg
Fidaxomicin
 873857-62-6 ≥99%
5mg
 ￥102.90 2023-09-02
S e l l e c k ZHONG GUO
S4227-50mg
Fidaxomicin
 873857-62-6 99.73%
50mg
 ￥799.79 2023-09-15
SHANG HAI YI EN HUA XUE JI SHU Co., Ltd.
R021816-250mg
Fidaxomicin
 873857-62-6 99%
250mg
 ￥1259 2024-05-21
SHANG HAI YI EN HUA XUE JI SHU Co., Ltd.
R021816-50mg
Fidaxomicin
 873857-62-6 99%
50mg
 ￥324 2024-05-21
ChemScence
CS-3249-5mg
Fidaxomicin
 873857-62-6 99.85%
5mg
 $50.0 2022-04-26
ChemScence
CS-3249-10mg
Fidaxomicin
 873857-62-6 99.85%
10mg
 $65.0 2022-04-26
ChemScence
CS-3249-50mg
Fidaxomicin
 873857-62-6 99.85%
50mg
 $90.0 2022-04-26

Fidaxomicin Suppliers

Suzhou Senfeida Chemical Co., Ltd
Gold Member
Audited Supplier Audited Supplier
(CAS:873857-62-6)FidaxoMicin
Order Number:sfd779
Stock Status:in Stock
Quantity:200kg
Purity:99.9%
Pricing Information Last Updated:Friday, 19 July 2024 14:32
Price ($):discuss personally

Fidaxomicin Related Literature

Related Categories

Additional information on Fidaxomicin

Introduction to Fidaxomicin (CAS No. 873857-62-6) in Modern Pharmaceutical Research

Fidaxomicin, a potent and highly selective antibiotic, is widely recognized for its efficacy in treating complex infections caused by Gram-negative bacteria. With the CAS No. 873857-62-6, this compound has garnered significant attention in the pharmaceutical industry due to its unique mechanism of action and minimal side effects. This introduction delves into the chemical properties, therapeutic applications, and recent advancements in research involving Fidaxomicin.

The chemical structure of Fidaxomicin belongs to the macrolide family, characterized by a large lactone ring and multiple sugar moieties. Its molecular formula, C??H??NO??, underscores its complex composition, which contributes to its high specificity against bacterial ribosomes. Unlike traditional macrolides such as erythromycin, Fidaxomicin exhibits enhanced stability in human serum, making it an attractive candidate for clinical use.

One of the most compelling aspects of Fidaxomicin is its mechanism of action. It binds to the 30S ribosomal subunit of Gram-negative bacteria, inhibiting protein synthesis by blocking the exit tunnel of nascent peptides. This targeted approach not only ensures high efficacy but also reduces the likelihood of bacterial resistance development. Recent studies have highlighted its exceptional activity against multidrug-resistant strains of *Escherichia coli* and *Pseudomonas aeruginosa*, which pose significant challenges in clinical settings.

The therapeutic applications of Fidaxomicin have expanded significantly over the past decade. Initially approved for the treatment of complicated urinary tract infections (cUTIs) and acute bacterial skin and skin structure infections (ABSSSIs), it has now been explored for broader indications. Clinical trials have demonstrated its effectiveness in patients with infections caused by carbapenem-resistant organisms, offering a promising alternative when traditional antibiotics fail.

Advances in synthetic chemistry have enabled the development of novel derivatives of Fidaxomicin with improved pharmacokinetic profiles. Researchers are investigating modifications to enhance its oral bioavailability and extend its spectrum of activity. For instance, studies have focused on incorporating fluorine atoms into its structure to bolster its antibacterial properties while maintaining safety.

The role of Fidaxomicin in antibiotic stewardship cannot be overstated. Its narrow spectrum and high efficacy make it an invaluable tool in combating resistant pathogens without promoting widespread resistance. Healthcare professionals are increasingly incorporating it into treatment guidelines for severe infections where other options are limited. This aligns with global efforts to address the growing crisis of antibiotic resistance.

Recent breakthroughs in microbiome research have also shed light on Fidaxomicin's potential beyond traditional infections. Studies suggest that it may modulate gut microbiota composition, offering insights into new therapeutic avenues for conditions like inflammatory bowel disease (IBD). While further research is needed, these findings underscore the compound's versatility and long-term potential.

The development of combination therapies involving Fidaxomicin is another area of active investigation. By pairing it with other antibiotics or antiviral agents, researchers aim to create synergistic effects that could overcome existing resistance mechanisms. Preliminary results from phase II trials indicate that such combinations may significantly reduce treatment duration while improving patient outcomes.

Regulatory agencies continue to monitor the use of Fidaxomicin closely to ensure its safe and effective application. Post-marketing surveillance programs have been instrumental in identifying rare adverse effects and optimizing dosing regimens. These efforts reflect a commitment to patient safety while maximizing therapeutic benefits.

In conclusion, Fidaxomicin (CAS No. 873857-62-6) represents a cornerstone in modern antibiotic therapy due to its unique properties and broad-spectrum activity against Gram-negative bacteria. Ongoing research continues to uncover new applications and improve upon its existing formulations, ensuring that it remains a critical asset in addressing infectious diseases worldwide.

873857-62-6 (Fidaxomicin) Related Products

Recommended suppliers
Suzhou Senfeida Chemical Co., Ltd
(CAS:873857-62-6)FidaxoMicin
sfd779
Purity:99.9%
Quantity:200kg
Price ($):Inquiry
Email